In fiscal year 2026, the company reported revenue of ¥117.0 billion (up 11% from FY 2025) with net income of ¥7.90 billion (up 39% from FY 2025) and profit margin expansion to 6.8% from 5.4%. In September 2025, Mochida agreed to acquire a 20% stake in And Pharma Co., Ltd. for ¥16.2 billion, signaling strategic expansion into emerging biotech partnerships. The company maintains a balanced dividend policy while pursuing selective M&A to strengthen its therapeutic pipeline.
Cyborg Score Rationale
Strong FY 2026 results with 11% revenue growth and 39% net income growth demonstrate operational momentum and margin expansion. However, a five-year track record of shrinking profits creates inconsistency concerns despite recent improvements. The company trades at a valuation premium to peers, limiting upside unless growth sustains.
Top Insights
FY 2026 marked inflection point: 11% revenue growth and 39% net income growth driven by operational leverage and margin expansion (6.8% vs. 5.4% prior year)
Strategic pivot toward partnerships: 20% stake acquisition in And Pharma (September 2025) for ¥16.2B signals M&A strategy to diversify pipeline beyond traditional generic focus
Shareholder returns active: ¥2 billion share repurchase program (valid through December 2026) and consistent 2.3-2.5% dividend yield support capital allocation discipline
Named Competitors
Takeda Pharmaceutical — Japan's largest pharma; diversified portfolio across oncology, gastroenterology, neurology
Daiichi Sankyo — Major Japanese pharma; focus on oncology, cardiovascular, and specialty medicines
Eisai — Integrated pharma with strong R&D in neurology, oncology, and specialty care
Shionogi — Mid-cap Japanese pharma; specialty focus on infectious disease and oncology
Recent Developments
(June 2026) Annual General Meeting held; FY 2026 results reported with strong earnings growth and margin expansion
(May 2026) Full year 2026 results announced: ¥117.0B revenue (+11%), ¥7.90B net income (+39%), profit margin 6.8%
(February 2026) Share repurchase program announced: up to 530,000 shares (1.5% of outstanding) for ¥2.0 billion, valid through December 2026
(September 2025) Acquisition agreement signed: 20% stake in And Pharma Co., Ltd. for ¥16.2 billion from Godo Kaisha JEH
Open the full interactive Mochida Pharmaceutical Co., Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.